首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1547701

全球鉅細胞病毒治療市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢和預測

Global Cytomegalovirus Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年07月01日 | 出版商:

Value Market Research | 英文 129 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球鉅細胞病毒治療市場需求預計將從 2023 年的 5.0222 億美元達到近 9.6448 億美元的市場規模，2024-2032 年研究期間複合年成長率為 7.52%。

鉅細胞病毒治療用於因皰疹家族病毒透過血液、唾液、尿液、精液和母乳等體液傳播而感染的患者。對於健康的兒童和成人來說，通常不需要鉅細胞病毒治療，並且他們無需藥物即可康復。但新生兒和免疫力較弱的人在出現鉅細胞病毒感染症狀時需要接受治療。治療方法主要取決於徵兆、症狀和嚴重程度。可以減緩病毒繁殖的抗病毒藥物是最常見的治療類型。用於治療和預防 CMV 的新藥物和疫苗正在不斷研究。

市場動態

CMV 感染和其他幾種病毒感染盛行率的上升將是推動該市場成長的關鍵趨勢。由於這種透過體液傳播的高傳染性病毒迅速傳播，全球器官移植和輸血數量的增加可以促進該市場的成長。民眾對感染的認知不斷提高，政府和私人組織增加資金支持治療該感染的臨床試驗，將有利於市場成長。這種鉅細胞病毒能夠感染所有年齡層的人，並產生更嚴重的症狀，影響眼睛、肺部、肝臟、食道、胃和腸道，這將進一步促進市場成長。高昂的治療成本和病毒在體內長期潛伏的能力將是阻礙該市場成長的主要限制因素。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對全球鉅細胞病毒治療市場的每個細分市場進行了包容性評估。鉅細胞病毒治療產業的成長和趨勢為本研究提供了整體方法。

市場區隔

鉅細胞病毒治療市場報告的這一部分提供了有關國家和區域級別細分市場的詳細資料，從而幫助策略師確定相應產品或服務的目標人口統計數據以及即將到來的機會。

依疾病類型

愛滋病
肝炎
流感
結核病
瘧疾
HPV病毒

按最終用途

醫院
診所
其他
傳染病治療

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲鉅細胞病毒治療市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。鉅細胞病毒治療市場的主要參與者包括吉利德科學公司、Chimerix、Clinigen Group PLC、默克公司、F. Hoffmann-La Roche Ltd、Fresenius Kabi、Genentech Inc.、Teva Pharmaceuticals Inc、Mylan NV、Thermo Fisher Scientific 、武田製藥、輝瑞。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 8 章：鉅細胞病毒治療公司的競爭格局

鉅細胞病毒治療市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 9 章：公司簡介

頂級公司市佔率分析
市場集中度
Gilead Sciences

公司概況
公司收入
產品
最新動態

Chimerix

公司概況
公司收入
產品
最新動態

Clinigen Group PLC

公司概況
公司收入
產品
最新動態

Merck & Co. Inc

公司概況
公司收入
產品
最新動態

F. Hoffmann-La Roche Ltd

公司概況
公司收入
產品
最新動態

Fresenius Kabi

公司概況
公司收入
產品
最新動態

Genentech Inc.

公司概況
公司收入
產品
最新動態

Teva Pharmaceuticals Inc

公司概況
公司收入
產品
最新動態

Mylan NV

公司概況
公司收入
產品
最新動態

Thermo Fisher Scientific

公司概況
公司收入
產品
最新動態

Takeda Pharmaceuticals

公司概況
公司收入
產品
最新動態

Pfizer

公司概況
公司收入
產品
最新動態

註 - 在公司概況中，財務詳細資訊和最新發展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR11213855

The global demand for Cytomegalovirus Treatment Market is presumed to reach the market size of nearly USD 964.48 Million by 2032 from USD 502.22 Million in 2023 with a CAGR of 7.52% under the study period 2024-2032.

Cytomegalovirus treatment is used in patients suffering an infection due to a virus belonging to the herpes family transmitted through body fluids like blood, saliva, urine, semen, and breast milk. Cytomegalovirus treatment is generally not necessary for healthy children and adults, and they recover without medication. But newborns and people who have weakened immunity undergo treatment when they are experiencing symptoms of CMV infection. The treatment method primarily depends on the signs, symptoms, and severity. Antiviral medications that can slow the reproduction of the virus are the most common type of treatment. New drugs and vaccines to treat and prevent CMV are continually being researched.

MARKET DYNAMICS

The rising prevalence of CMV infections and several other viral infections will be the crucial trend propelling this market's growth. An increase in the number of organ transplants and blood transfusion carried out worldwide can boost this market's growth due to the rapid spread of this highly infectious virus transmitted through body fluids. Growing public awareness about the infection and increased funding from the government and private organizations to support clinical trials for treating the same will benefit market growth. This CMV's nature to infect people of all age groups and have more severe symptoms affecting the eyes, lungs, liver, esophagus, stomach, and intestines will further enhance market growth. The high treatment costs and the virus's ability to remain latent within the body over long periods will be the main restraints hindering this market's growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Cytomegalovirus Treatment. The growth and trends of Cytomegalovirus Treatment industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Cytomegalovirus Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Disease Type

HIV
Hepatitis
Influenza
TB
Malaria
HPV

By End Use

Hospitals
Clinics
Others
Infectious Disease Therapeutics

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Cytomegalovirus Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Cytomegalovirus Treatment market include Gilead Sciences, Chimerix, Clinigen Group PLC, Merck & Co. Inc, F. Hoffmann-La Roche Ltd, Fresenius Kabi, Genentech Inc., Teva Pharmaceuticals Inc, Mylan N.V, Thermo Fisher Scientific, Takeda Pharmaceuticals, Pfizer. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. CYTOMEGALOVIRUS TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Disease Type
- 3.7.2 Market Attractiveness Analysis By End Use
- 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET ANALYSIS BY DISEASE TYPE

5.1. Overview By Disease Type
5.2. Historical and Forecast Data
5.3. Analysis By Disease Type
5.4. HIV Historic and Forecast Sales By Regions
5.5. Hepatitis Historic and Forecast Sales By Regions
5.6. Influenza Historic and Forecast Sales By Regions
5.7. TB Historic and Forecast Sales By Regions
5.8. Malaria Historic and Forecast Sales By Regions
5.9. HPV Historic and Forecast Sales By Regions

6. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET ANALYSIS BY END USE

6.1. Overview By End Use
6.2. Historical and Forecast Data
6.3. Analysis By End Use
6.4. Hospitals Historic and Forecast Sales By Regions
6.5. Clinics Historic and Forecast Sales By Regions
6.6. Others Historic and Forecast Sales By Regions
6.7. Infectious Disease Therapeutics Historic and Forecast Sales By Regions

7. GLOBAL CYTOMEGALOVIRUS TREATMENT MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1 Overview, Historic and Forecast Data Sales Analysis
- 7.3.2 North America By Segment Sales Analysis
- 7.3.3 North America By Country Sales Analysis
- 7.3.4 United States Sales Analysis
- 7.3.5 Canada Sales Analysis
- 7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1 Overview, Historic and Forecast Data Sales Analysis
- 7.4.2 Europe By Segment Sales Analysis
- 7.4.3 Europe By Country Sales Analysis
- 7.4.4 United Kingdom Sales Analysis
- 7.4.5 France Sales Analysis
- 7.4.6 Germany Sales Analysis
- 7.4.7 Italy Sales Analysis
- 7.4.8 Russia Sales Analysis
- 7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1 Overview, Historic and Forecast Data Sales Analysis
- 7.5.2 Asia Pacific By Segment Sales Analysis
- 7.5.3 Asia Pacific By Country Sales Analysis
- 7.5.4 China Sales Analysis
- 7.5.5 India Sales Analysis
- 7.5.6 Japan Sales Analysis
- 7.5.7 South Korea Sales Analysis
- 7.5.8 Australia Sales Analysis
- 7.5.9 South East Asia Sales Analysis
- 7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1 Overview, Historic and Forecast Data Sales Analysis
- 7.6.2 Latin America By Segment Sales Analysis
- 7.6.3 Latin America By Country Sales Analysis
- 7.6.4 Brazil Sales Analysis
- 7.6.5 Argentina Sales Analysis
- 7.6.6 Peru Sales Analysis
- 7.6.7 Chile Sales Analysis
- 7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1 Overview, Historic and Forecast Data Sales Analysis
- 7.7.2 Middle East & Africa By Segment Sales Analysis
- 7.7.3 Middle East & Africa By Country Sales Analysis
- 7.7.4 Saudi Arabia Sales Analysis
- 7.7.5 UAE Sales Analysis
- 7.7.6 Israel Sales Analysis
- 7.7.7 South Africa Sales Analysis
- 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE CYTOMEGALOVIRUS TREATMENT COMPANIES

8.1. Cytomegalovirus Treatment Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9. COMPANY PROFILES OF CYTOMEGALOVIRUS TREATMENT INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Gilead Sciences
- 9.3.1 Company Overview
- 9.3.2 Company Revenue
- 9.3.3 Products
- 9.3.4 Recent Developments
9.4. Chimerix
- 9.4.1 Company Overview
- 9.4.2 Company Revenue
- 9.4.3 Products
- 9.4.4 Recent Developments
9.5. Clinigen Group PLC
- 9.5.1 Company Overview
- 9.5.2 Company Revenue
- 9.5.3 Products
- 9.5.4 Recent Developments
9.6. Merck & Co. Inc
- 9.6.1 Company Overview
- 9.6.2 Company Revenue
- 9.6.3 Products
- 9.6.4 Recent Developments
9.7. F. Hoffmann-La Roche Ltd
- 9.7.1 Company Overview
- 9.7.2 Company Revenue
- 9.7.3 Products
- 9.7.4 Recent Developments
9.8. Fresenius Kabi
- 9.8.1 Company Overview
- 9.8.2 Company Revenue
- 9.8.3 Products
- 9.8.4 Recent Developments
9.9. Genentech Inc.
- 9.9.1 Company Overview
- 9.9.2 Company Revenue
- 9.9.3 Products
- 9.9.4 Recent Developments
9.10. Teva Pharmaceuticals Inc
- 9.10.1 Company Overview
- 9.10.2 Company Revenue
- 9.10.3 Products
- 9.10.4 Recent Developments
9.11. Mylan N.V
- 9.11.1 Company Overview
- 9.11.2 Company Revenue
- 9.11.3 Products
- 9.11.4 Recent Developments
9.12. Thermo Fisher Scientific
- 9.12.1 Company Overview
- 9.12.2 Company Revenue
- 9.12.3 Products
- 9.12.4 Recent Developments
9.13. Takeda Pharmaceuticals
- 9.13.1 Company Overview
- 9.13.2 Company Revenue
- 9.13.3 Products
- 9.13.4 Recent Developments
9.14. Pfizer
- 9.14.1 Company Overview
- 9.14.2 Company Revenue
- 9.14.3 Products
- 9.14.4 Recent Developments